A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL)

Trial Profile

A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs ME 401 (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors MEI Pharma
  • Most Recent Events

    • 31 May 2017 According to an MEI Pharma media release, an independent Safety Review Committee has completed its pre-specified review of the first cohort of six evaluable patients and declared a minimum biologically effective dose (mBED) for ME-401 at the starting dose of 60 mg and recommended escalation to a 120 mg dose cohort. Full data will be submitted for presentation at an upcoming scientific meeting.
    • 04 May 2017 According to a MEI Pharma media release, interim safety and efficacy data from the first cohort of the study are expected in June.
    • 08 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top